SAN DIEGO—An increasing number of patients is being identified with deficiency of adenosine deaminase type 2 (DADA2); fortunately, researchers and clinicians continue to better understand the genetic disease as well, experts said in a session at the 2017 ACR/ARHP Annual Meeting Nov. 3–8. The childhood-onset disease involves loss-of-function mutations to the CECR1 gene (i.e., cat…
ADA2 Mutation Connects Vascular Pathology to Immunodeficiency
Two new studies that examine the effects of a genetic defect in adenosine deaminase 2 may advance a gene-based definition of vasculopathy